<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - 獲取免費報告) 的股價在週四交易中下跌了 6.8%。該公司的股價最低曾達到 5.67 美元，最後交易價為 5.6280 美元。在午盤交易中，共成交了 1,886,479 股，較平均交易量 2,872,656 股下降了 34%。該股票此前收盤價為 6.04 美元。</p>
<p>獲取 <strong>Compass Therapeutics</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<ul>
<li>分析師仍看好的三大高動量公司</li>
</ul>
<p>CMPX 已成為幾份研究報告的主題。Cantor Fitzgerald 於 12 月 3 日星期三在一份研究報告中開始覆蓋 Compass Therapeutics。他們對該股票給予了 “增持” 評級。花旗集團在 12 月 3 日星期三的研究報告中開始覆蓋 Compass Therapeutics 的股票。他們對該公司給予了 “跑贏大盤” 的評級。Leerink Partners 在 11 月 26 日星期三的研究報告中將 Compass Therapeutics 的股票評級提升至 “強力買入”。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Compass Therapeutics 股票的 “賣出（d-）” 評級。最後，Raymond James Financial 在 1 月 6 日星期二的研究報告中重新發布了 “跑贏大盤” 評級，並設定了 9.00 美元的目標價。一位股票研究分析師對該股票給予了強力買入評級，十四位分析師給予了買入評級，一位分析師對該公司給予了賣出評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 12.23 美元。</p>
<p><strong>查看我們關於 CMPX 的最新報告</strong></p>
<h2>Compass Therapeutics 股票下跌 4.2%</h2>
<p>該股票的市值為 10.3 億美元，市盈率為-12.86，貝塔值為 1.45。該公司的 50 日簡單移動平均線為 5.13 美元，200 日簡單移動平均線為 3.99 美元。</p>
<p>Compass Therapeutics (NASDAQ:CMPX - 獲取免費報告) 最近於 11 月 5 日星期三發佈了其財報。該公司報告每股收益（EPS）為-0.08 美元，超出分析師的共識預期-0.14 美元，超出幅度為 0.06 美元。整體來看，分析師預計 Compass Therapeutics, Inc. 在本年度將發佈-0.36 美元的每股收益。</p>
<h2>對 Compass Therapeutics 的對沖基金看法</h2>
<p>機構投資者和對沖基金最近對該公司的持倉進行了調整。Suvretta Capital Management LLC 在第三季度將其在 Compass Therapeutics 的股份增加了 97.2%。Suvretta Capital Management LLC 現在擁有該公司 14,101,159 股股票，價值 49,354,000 美元，此前在該期間內購買了額外的 6,951,666 股。Vivo Capital LLC 在第三季度將其在 Compass Therapeutics 的持倉增加了 57.9%。Vivo Capital LLC 現在擁有該公司 9,545,466 股股票，價值 33,409,000 美元，此前在上個季度購買了額外的 3,502,000 股。先鋒集團在第三季度將其在 Compass Therapeutics 的持倉增加了 45.6%。先鋒集團現在擁有該公司 7,062,799 股股票，價值 24,720,000 美元，此前在該期間內購買了額外的 2,212,794 股。Adage Capital Partners GP L.L.C. 在第二季度將其在 Compass Therapeutics 的持倉增加了 11.3%。Adage Capital Partners GP L.L.C. 現在擁有該公司 4,424,868 股股票，價值 11,505,000 美元，此前在該期間內購買了額外的 449,868 股。最後，Millennium Management LLC 在第三季度將其在 Compass Therapeutics 的持倉增加了 280.4%。Millennium Management LLC 現在擁有該公司 3,237,572 股股票，價值 11,332,000 美元，此前在上個季度購買了額外的 2,386,367 股。機構投資者和對沖基金持有該公司 68.43% 的股份。</p>
<h2>關於 Compass Therapeutics</h2>
<p>(獲取免費報告)</p>
<p>Compass Therapeutics, Inc 是一家臨牀階段的生物技術公司，致力於新型免疫腫瘤療法的發現和開發。公司總部位於馬薩諸塞州劍橋，專注於工程化單克隆抗體候選藥物，旨在增強 T 細胞介導的抗腫瘤反應。Compass 利用專有抗體平台識別和優化調節免疫檢查點通路和腫瘤微環境的生物製劑。</p>
<p>該公司的主要項目包括 CTX-471，一種雙特異性抗體，靶向 PD-1 和 PD-L1 檢查點，以及 DSP107，一種 CD47-SIRPα 通路調節劑，旨在破壞癌細胞上的 “別吃我” 信號。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Compass Therapeutics</li>
<li>Elon 將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>執行命令 14330：特朗普最大的舉措</li>
<li>崩盤已經開始（大多數人只是不知道而已）</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元在 Compass Therapeutics 嗎？</h2>
<p>在您考慮 Compass Therapeutics 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Compass Therapeutics 並不在名單上。</p>
<p>雖然 Compass Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CMPX

<p>Compass Therapeutics（納斯達克代碼：CMPX）股價下跌 6.8%，至 5.6280 美元，交易量較平均水平下降 34%。分析師的評級意見不一，Cantor Fitzgerald 和花旗集團分別給予 “增持” 和 “跑贏大盤” 的評級，而 Weiss Ratings 則維持 “賣出” 評級。該公司的市值為 10.3 億美元，市場共識評級為 “適度買入”，目標價為 12.23 美元。機構投資者持有 68.43% 的股份，多個對沖基金的持股比例顯著增加。該公司專注於免疫腫瘤治療，報告的每股收益為（-0.08 美元），超出預期</p>

<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report)'s share price traded down 6.8% during trading on Thursday . The company traded as low as $5.67 and last traded at $5.6280. 1,886,479 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 2,872,656 shares. The stock had previously closed at $6.04.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc. (NASDAQ:CMPX - 獲取免費報告) 的股價在週四交易中下跌了 6.8%。該公司的股價最低曾達到 5.67 美元，最後交易價為 5.6280 美元。在午盤交易中，共成交了 1,886,479 股，較平均交易量 2,872,656 股下降了 34%。該股票此前收盤價為 6.04 美元。</p>
</div><p>Get <strong>Compass Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Compass Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><ul>
<li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師仍看好的三大高動量公司</li>
</ul>
</div><p>CMPX has been the topic of several research reports. Cantor Fitzgerald assumed coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an &#34;overweight&#34; rating on the stock. Citigroup assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an &#34;outperform&#34; rating for the company. Leerink Partnrs raised shares of Compass Therapeutics to a &#34;strong-buy&#34; rating in a research report on Wednesday, November 26th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. Finally, Raymond James Financial reissued an &#34;outperform&#34; rating and set a $9.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $12.23.</p>
<div class="lb-trans"><p>CMPX 已成為幾份研究報告的主題。Cantor Fitzgerald 於 12 月 3 日星期三在一份研究報告中開始覆蓋 Compass Therapeutics。他們對該股票給予了 “增持” 評級。花旗集團在 12 月 3 日星期三的研究報告中開始覆蓋 Compass Therapeutics 的股票。他們對該公司給予了 “跑贏大盤” 的評級。Leerink Partners 在 11 月 26 日星期三的研究報告中將 Compass Therapeutics 的股票評級提升至 “強力買入”。Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Compass Therapeutics 股票的 “賣出（d-）” 評級。最後，Raymond James Financial 在 1 月 6 日星期二的研究報告中重新發布了 “跑贏大盤” 評級，並設定了 9.00 美元的目標價。一位股票研究分析師對該股票給予了強力買入評級，十四位分析師給予了買入評級，一位分析師對該公司給予了賣出評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 12.23 美元。</p>
</div><p><strong>Check Out Our Latest Report on CMPX</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CMPX 的最新報告</strong></p>
</div><h2>Compass Therapeutics Stock Down 4.2%</h2>
<div class="lb-trans"><h2>Compass Therapeutics 股票下跌 4.2%</h2>
</div><p>The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -12.86 and a beta of 1.45. The company's fifty day simple moving average is $5.13 and its 200 day simple moving average is $3.99.</p>
<div class="lb-trans"><p>該股票的市值為 10.3 億美元，市盈率為-12.86，貝塔值為 1.45。該公司的 50 日簡單移動平均線為 5.13 美元，200 日簡單移動平均線為 3.99 美元。</p>
</div><p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.06. As a group, analysts anticipate that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>Compass Therapeutics (NASDAQ:CMPX - 獲取免費報告) 最近於 11 月 5 日星期三發佈了其財報。該公司報告每股收益（EPS）為-0.08 美元，超出分析師的共識預期-0.14 美元，超出幅度為 0.06 美元。整體來看，分析師預計 Compass Therapeutics, Inc. 在本年度將發佈-0.36 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Compass Therapeutics</h2>
<div class="lb-trans"><h2>對 Compass Therapeutics 的對沖基金看法</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the company. Suvretta Capital Management LLC increased its stake in shares of Compass Therapeutics by 97.2% during the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company's stock worth $49,354,000 after purchasing an additional 6,951,666 shares during the period. Vivo Capital LLC grew its holdings in Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company's stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. Vanguard Group Inc. increased its position in Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company's stock worth $24,720,000 after buying an additional 2,212,794 shares during the period. Adage Capital Partners GP L.L.C. increased its position in Compass Therapeutics by 11.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company's stock worth $11,505,000 after buying an additional 449,868 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Compass Therapeutics by 280.4% during the third quarter. Millennium Management LLC now owns 3,237,572 shares of the company's stock worth $11,332,000 after buying an additional 2,386,367 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近對該公司的持倉進行了調整。Suvretta Capital Management LLC 在第三季度將其在 Compass Therapeutics 的股份增加了 97.2%。Suvretta Capital Management LLC 現在擁有該公司 14,101,159 股股票，價值 49,354,000 美元，此前在該期間內購買了額外的 6,951,666 股。Vivo Capital LLC 在第三季度將其在 Compass Therapeutics 的持倉增加了 57.9%。Vivo Capital LLC 現在擁有該公司 9,545,466 股股票，價值 33,409,000 美元，此前在上個季度購買了額外的 3,502,000 股。先鋒集團在第三季度將其在 Compass Therapeutics 的持倉增加了 45.6%。先鋒集團現在擁有該公司 7,062,799 股股票，價值 24,720,000 美元，此前在該期間內購買了額外的 2,212,794 股。Adage Capital Partners GP L.L.C. 在第二季度將其在 Compass Therapeutics 的持倉增加了 11.3%。Adage Capital Partners GP L.L.C. 現在擁有該公司 4,424,868 股股票，價值 11,505,000 美元，此前在該期間內購買了額外的 449,868 股。最後，Millennium Management LLC 在第三季度將其在 Compass Therapeutics 的持倉增加了 280.4%。Millennium Management LLC 現在擁有該公司 3,237,572 股股票，價值 11,332,000 美元，此前在上個季度購買了額外的 2,386,367 股。機構投資者和對沖基金持有該公司 68.43% 的股份。</p>
</div><h2>About Compass Therapeutics</h2>
<div class="lb-trans"><h2>關於 Compass Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc 是一家臨牀階段的生物技術公司，致力於新型免疫腫瘤療法的發現和開發。公司總部位於馬薩諸塞州劍橋，專注於工程化單克隆抗體候選藥物，旨在增強 T 細胞介導的抗腫瘤反應。Compass 利用專有抗體平台識別和優化調節免疫檢查點通路和腫瘤微環境的生物製劑。</p>
</div><p>The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.</p>
<div class="lb-trans"><p>該公司的主要項目包括 CTX-471，一種雙特異性抗體，靶向 PD-1 和 PD-L1 檢查點，以及 DSP107，一種 CD47-SIRPα 通路調節劑，旨在破壞癌細胞上的 “別吃我” 信號。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Compass Therapeutics</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Compass Therapeutics</li>
<li>Elon 將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>執行命令 14330：特朗普最大的舉措</li>
<li>崩盤已經開始（大多數人只是不知道而已）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Compass Therapeutics 嗎？</h2>
</div><p>Before you consider Compass Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Compass Therapeutics 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Compass Therapeutics 並不在名單上。</p>
</div><p>While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Compass Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Compass Therapeutics (NASDAQ:CMPX) 股價下跌 6.8% - 現在是賣出的時候嗎？